Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries

Health Policy

Volumn 117, Issue 3, 2014, Pages 311-327

  Vogler, Sabine ^a   Habimana, Katharina ^a   Arts, Danielle ^a,b  

^a GESUNDHEIT ÖSTERREICH GMBH   (Austria)

^b LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

Author keywords

Community pharmacy; Deregulation; Europe; Policy change

Indexed keywords

NON PRESCRIPTION DRUG;

ARTICLE; AUSTRIA; COMPETITION; DENMARK; DRUG COST; EUROPEAN; FINLAND; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; IRELAND; NORWAY; PHARMACIST; PHARMACY; SPAIN; SWEDEN; UNITED KINGDOM; COMMERCIAL PHENOMENA; COST; ECONOMICS; EUROPE; FEE; GOVERNMENT REGULATION; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; QUESTIONNAIRE; STANDARDS;

COMMERCE; COMMUNITY PHARMACY SERVICES; COSTS AND COST ANALYSIS; EUROPE; FEES, PHARMACEUTICAL; GOVERNMENT REGULATION; HEALTH SERVICES ACCESSIBILITY; NONPRESCRIPTION DRUGS; PHARMACIES; SURVEYS AND QUESTIONNAIRES;

EID: 84908152532     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2014.06.001     Document Type: Article

References (106)

1. Bernsten C., Gariepy Y., Lutz E.M., Reid P.W., Schneider P.J. Developing new economic models for payment for services by pharmacists. International Pharmacy Journal 2009, 2:25.
2. PPRI Network Members (several authors). PPRI/PHIS Pharma Profiles - country reports on pharmaceutical systems and policies. Vienna. Available at: ; 2007-2012. http://whocc.goeg.at/Publications/CountryReports.
3. Noyce P.R. Providing patient care through community pharmacies in the UK: policy, practice, and research. Annals of Pharmacotherapy 2007, 41(5):861-868.
4. Silcock J., Raynor D., Petty D. The organisation and development of primary care pharmacy in the United Kingdom. Health Policy 2004, 67(2):207.
5. Anell A. Deregulating the pharmacy market: the case of Iceland and Norway. Health Policy 2005, 75:9-17.
6. Traulsen J.M., Almarsdóttir A.B. The argument for pharmaceutical policy. Pharmacy World and Science 2005, 27(1):7-12.
7. Balgård M. The new pharmacy market in Sweden. European Journal of Hospital Pharmacy: Science and Practice 2012, 19(1):23-25.
8. Hepler C.D., Strand L.M. Opportunities and responsibilities in pharmaceutical care. American Journal of Hospital Pharmacy 1990, 47(3):533-543.
9. Mossialos E., Naci H., Courtin E. Expanding the role of community pharmacists: policymaking in the absence of policy-relevant evidence?. Health Policy 2013, 111(2):135-148.
10. Wiedenmayer K., Summers R.S., Mackie C.A., Gous A.G., Everard M. Developing pharmacy practice: a focus on patient care. Handbook 2006, World Health Organisation, Geneva.
11. Beney J., Bero L., Bond C.M. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes 2000, The Cochrane Library.
12. Nkansah N., Mostovetsky O., Yu C., Chheng T., Beney J., Bond C.M., et al. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database of Systematic Reviews 2010, 7(7).
13. Ellitt G.R., Brien J.E., Aslani P., Chen T.F. Quality patient care and pharmacists' role in its continuity-a systematic review. Annals of Pharmacotherapy 2009, 43(4):677-691.
14. WSMI SWITCH - prescription to nonprescription switch 2009, The World Self-Medication Industry.
15. Francis S.A., Barnett N., Denham M. Switching of prescription drugs to over-the-counter status. Drugs & Aging 2005, 22(5):361-370.
16. Paudyal V., Hansford D., Cunningham S., Stewart D. Pharmacy assisted patient self care of minor ailments: a chronological review of UK health policy documents and key events 1997-2010. Health Policy 2011, 101(3):253-259.
17. Van Mil J., Schulz M. A review of pharmaceutical care in community pharmacy in Europe. Harvard Health Policy Review 2006, 7(1):155-168.
18. Hughes C.M., Hawwa A.F., Scullin C., Anderson C., Bernsten C.B., Björnsdóttir I., et al. Provision of pharmaceutical care by community pharmacists: a comparison across Europe. Pharmacy World & Science 2010, 32(4):472-487.
19. Vogler S., Zimmermann N., Leopold C., de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Review 2011, 4(2):22-32.
20. Bernsten C., Andersson K., Gariepy Y., Simoens S. A comparative analysis of remuneration models for pharmaceutical professional services. Health Policy 2010, 95(1):1.
21. Kanavos P., Seeley L., Vandoros S. Tender systems for outpatient pharmaceuticals in the European Union: evidence from the Netherlands, Germany and Belgium 2009, European Medicines Information Network (EMINet).
22. Dylst P., Vulto A., Simoens S. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe?. Health Policy 2011, 101(2):146-152.
23. Habl C., Vogler S., Leopold C., Schmickl B., Fröschl B. Referenzpreissysteme in Europa. Analyse und Umsetzungsvoraussetzungen für Österreich 2008, ÖBIG Forschungs- und Planungsgesellschaft mbH, Vienna.
24. Lluch M. Are regulations of community pharmacies in Europe questioning our pro-competitive policies?. Eurohealth 2009, 15(4):26.
25. Competition Authority Submission of the Competition Authority to the Pharmacy Review Group. Dublin; 2001.
26. Gorecki P. Do you believe in magic? Improving the quality of pharmacy services through restricting entry and aspirational contracts, the Irish experience. European Journal of Health Economics 2011, 12(6):521-531.
27. OFT The control of entry regulations and retail pharmacy services in UK 2003, Office of Fair Trading (OFT).
28. Blöndal M. Re-regulating the Swedish pharmacy system-analysing arguments of key actors. A documentary analysis 2009, University of Iceland, Faculty of Pharmaceutical Science-School of Health Science.
29. Lluch M., Kanavos P. Impact of regulation of community pharmacies on efficiency, access and equity. Evidence from the UK and Spain. Health Policy 2010, 95(2-3):245-254.
30. Volkerink B., de Bas P., van Gorp N., Philipsen N. Study of regulatory restrictions in the field of pharmacies. Report for the European Commission 2007, Internal Market and Services DG Rotterdam, ECORYS Nederland BV.
31. Dalen D.M. Legemiddelmarkedet etter apotekreformen: Regulering, markedsstruktur og konkurranse 2003, Norwegian Competition Authority, Sandvika.
32. PGEU European Pharmacists Welcome the Closure of all Pending Infringement Proceedings against the Community Pharmacy Sector. Press Release. 24 November 2011, Available from: http://www.pgeu.org/Portals/6/documents/2011/Press%20Raleases/11%2011%2024E%20009PR%20PGEU%20PR%20on%20Infringements.pdf [accessed 11.12.11].
33. European Court of Justice. C-531/06 Commission v Italy and C-171/07 and C-172/07 Apothekerkammer des Saarlandes a.o. v Saarland, judgments of 19 May 2009.
34. Econ Analyse AS Evaluering av apotekloven og indeksprissystemet. Rapport 2004-010 2004, Commissioned by the Ministry of Health, Oslo.
35. Statskontoret En omreglerad apoteksmarknad - delrapport 2 [A deregulated pharmacy market - interim report 2]. Stockholm; 2012.
36. Statskontoret En omreglerad apoteksmarknad - slutrapport [A deregulated pharmacy market - Final report]. Stockholm; 2013.
37. Statskontoret En omreglerad apoteksmarknad - delrapport 1 [A deregulated pharmacy market - interim report 1]. Stockholm; 2011.
38. TLV 2012 års översyn av apotekens handelsmarginal - en samlad bedömning av ersättningen till apoteksmarknaden. Slutrapport 2012, April, Stockholm.
39. Tillväxtanalys (Swedish Agency for Growth Policy Analysis) Geografisk tillgänglighe till läkemedel. En analys av omregleringen av apoteksmarknaden - Slutrapport 2012.
40. Tillväxtanalys (Swedish Agency for Growth Policy Analysis) Kostnadsutvecklingen för läkemedel på den omreglerade apoteksmarknaden 2013.
41. Konsumentverket [Swedish Consumers Agency] Omregleringen av apoteksmarknaden - Redovisning av ett regeringsuppdrag 2011, Stockholm: Report 2011.
42. OFT Evaluating the impact of the 2003 OFT study on the Control of Entry regulations in the retail pharmacies market 2010, Office of Fair Trading (OFT).
43. Konkurrensverket [Competiton Authority] Omregleringen av apoteksmarknaden - Redovisning av regeringsuppdrag 2010, Konkurrensverkets rapportserie, Stockholm, [04.12.10].
44. Konkurransetilsynet Konkurransen i Norge. Bergen 2009; Available from: . http://www.konkurransetilsynet.no/ImageVault/Images/Id_1817/ImageVaultHandler.aspx.
45. Morgall J.M., Almarsdóttir A.B. No struggle, no strength: how pharmacists lost their monopoly. Social Science & Medicine 1999, 48(9):1247-1258.
46. Anell A., Hjelmgren J. Implementing competition in the pharmacy sector: lessons from Iceland and Norway. Applied Health Economics and Health Policy 2002, 1(3):149.
47. Rudholm N. Entry of new pharmacies in the deregulated Norwegian pharmaceuticals market - consequences for costs and availability. Health Policy 2008, 87:258-263.
48. Vogler S., Arts D., Habl C. Community pharmacy in Europe. Lessons from deregulation - case studies 2006, ÖBIG, Vienna.
49. Garattini L., van de Vooren K., Curto A. Will the reform of community pharmacies in Italy be of benefit to patients or the Italian National Health Service?. Drugs & Therapy Perspectives 2012, 28(11):23-26.
50. Mossialos E., Mrazek M.F. The regulation of pharmacies in six countries: report prepared for the Office of Fair Trading 2003, LSE Health & Social Care and the European Observatory on Health Care Systems.
51. WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Glossary of pharmaceutical terms. Update 2013 2013, Vienna.
52. Eurostat. Eurostat Health Database.
53. NHS Prescriptions dispensed in the community: England, statistics for 2000 to 2010 2011, The NHS Information Centre for Health and Social Care, United Kingdom.
54. OECD Health data 2013, June, OECD, Paris.
55. Hussain S. Hur har arbetsmiljön på apoteken påverkats av omregleringen av apoteksmarknaden? 2013, Linneuniversitetet, Kalmar.
56. SVT. Mer smink - mindre mediciner. [03.09.13]. http://www.svt.se/nyheter/sverige/smink-istallet-for-mediciner-pa-apoteken.
57. IPU. Annual Reports. Kilkenny Irish Pharmacy Union, several years.
58. Health and Social Care Information Centre (HSCIC) General pharmaceutical services in England 2003-04 to 2012-13 2013, The NHS Information Centre for Health and Social Care, United Kingdom.
59. Apotekforeningen Facts and figures, pharmacies and pharmaceuticals in Norway 2005-2010, Norwegian Pharmacy Association.
60. Redman T., Köping Höggärd M. PPRI Pharma Profile Sweden 2007, Pharmaceutical Pricing and Reimbursement Information (PPRI), Vienna.
61. Sveriges Apoteksförening Branschrapport 2012 2013.
62. Danmarks Apotekerforening Lægemidler i Danmark 2012 Lægemiddelforbrug og apoteksdrift i Danmark 2012, Danmarks Apotekerforening.
63. SFK Data en feiten 2013, Stichting Farmaceutische Kengetallen, The Hague.
64. Brekke K.R., Holm T.H., Straume O.R. Margins and market shares: pharmacy incentives for generic substitution. European Economic Review 2013, 61:116-131.
65. Henricson M., Rosklint E. Den omreglerade apoteksmarknaden: En studie av förändringen i lokalisering på den svenska marknaden 2012, Linköping.
66. Borrell J.R., Fernandez-Villadangos L. Clustering or scattering: the underlying reason for regulating distance among retail outlets. Preliminary draft 2010.
67. Vogler S., Habl C., Leopold C., Rosian-Schikuta I. PPRI Report 2008, Gesundheit Österreich GmbH/Geschäftsbereich ÖBIG, Vienna.
68. AESGP Legal classification status of selected ingredients in Europe, List 1 and List 2, as 31 January 2011 2011, Association of the European Self-Medication Industry, Brussels.
69. Nordén-Hägg A., Shamoon M., Kälvemark Sporrong S. Deregulation of nonprescription medicines in Sweden-a look at the control system. Research in Social and Administrative Pharmacy 2012, 8(6):567-573.
70. Larsen J.B., Vrangbæk K., Traulsen J.M. Advocacy coalitions and pharmacy policy in Denmark-solid cores with fuzzy edges. Social Science & Medicine 2006, 63(1):212-224.
71. PGEU PGEU statement on medicine shortages in European community pharmacies 2013.
72. Gray A., Manasse H.R. Shortages of medicines: a complex global challenge. Bulletin of the World Health Organization 2012, 90(3):158.
73. Thyberg M. The regulation of the pharmacy market in Sweden. PPRI network meeting 2010, [unpublished presentation].
74. Sveriges Apoteksförening Apoteksbranschens årsrapport 2010 2011.
75. Apoteket Annual Report 2009 2009, Apoteket AB.
76. Bond C., Blenkinsopp A., Inch J., Celino G., Gray N. The effect of the new community pharmacy contract on the community pharmacy workforce 2008, Pharmacy Practice Research Trust, London.
77. Hassell K., Seston E.M., Schafheutle E.I., Wagner A., Eden M. Workload in community pharmacies in the UK and its impact on patient safety and pharmacists' well-being: a review of the evidence. Health & Social Care in the Community 2011, 19(6):561-575.
78. Carlén E. Privatisering Rätt medicin för apotekspersonalen? 2011, Stockholm.
79. Tully M.P., Beckman-Gyllenstrand A., Bernsten C.B. Factors predicting poor counselling about prescription medicines in Swedish community pharmacies. Patient Education and Counseling 2011, 83(1):3-6.
80. Olsson E., Ingman P., Ahmed B., Kälvemark Sporrong S. Pharmacist-patient communication in Swedish community pharmacies. Research in Social and Administrative Pharmacy 2014, 10(1):149-155.
81. Bardage C., Westerlund T., Barzi S., Bernsten C. Non-prescription medicines for pain and fever-a comparison of recommendations and counseling from staff in pharmacy and general sales stores. Health Policy 2013, 110(1):76-83.
82. Kälvemark Sporrong S, Nordén-Hägg A. Patient safety in Swedish community pharmacies after reregulation of conditions. Unpublished article, cited in Danmarks Apotekerforening Forskere: Patientsikkerhed faldet signifikant efter svensk apoteksliberalisering [Researchers: Patient safety decreased significantly after the Swedish pharmacy liberalization]. Available from: [accessed 02.09.13]. http://wwwapotekerforeningendk/presse-og-nyhedsbreve/nyhedsbreve/~/media/Apotekerforeningen/analysersundhed/01052013_patientsikkerhed_nyhedsbrevashx.
83. Svarstad B.L., Bultman D.C., Mount J.K. Patient counseling provided in community pharmacies: effects of state regulation, pharmacist age, and busyness. Journal of the American Pharmaceutical Association 2004, 44(1):22-29.
84. Schafheutle E.I., Seston E.M., Hassell K. Factors influencing pharmacist performance: a review of the peer-reviewed literature. Health Policy 2011, 102(2):178-192.
85. McCann L., Adair C.G., Hughes C.M. An exploration of work-related stress in Northern Ireland community pharmacy: a qualitative study. International Journal of Pharmacy Practice 2009, 17(5):261-267.
86. Gaither C.A., Kahaleh A.A., Doucette W.R., Mott D.A., Pederson C.A., Schommer J.C. A modified model of pharmacists' job stress: the role of organizational, extra-role, and individual factors on work-related outcomes. Research in Social and Administrative Pharmacy 2008, 4(3):231-243.
87. Lea V.M., Corlett S.A., Rodgers R.M. Workload and its impact on community pharmacists' job satisfaction and stress: a review of the literature. International Journal of Pharmacy Practice 2012, 20(4):259-271.
88. Bush J., Langley C.A., Wilson K.A. The corporatization of community pharmacy: implications for service provision, the public health function, and pharmacy's claims to professional status in the United Kingdom. Research in Social and Administrative Pharmacy 2009, 5(4):305-318.
89. Kanavos P., Vandoros S., Irwin R., Nicod E., Casson M. Differences in costs of and access to pharmaceutical products in the EU 2011, European Parliament, Brussels.
90. Vogler S., Zimmermann N., Habl C. Understanding the components of pharmaceutical expenditure - overview of pharmaceutical policies influencing expenditure across European countries. Generics and Biosimilars Initiative (GaBI) Journal 2013, [in press].
91. Almarsdóttir A., Traulsen J. Cost-containment as part of pharmaceutical policy. Pharmacy World and Science 2005, 27(3):144-148.
92. Kanavos P.G., Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Economics Policy and Law 2011, 6(3):337.
93. Brekke K.R., Dalen D.M., Strøm S. Should pharmaceutical costs be curbed?. Nordic Economic Policy Review 2012, (2):247-273.
94. OECD Pharmaceutical pricing policies in a global market 2008, OECD, Paris.
95. Bouvy J., Vogler S. Background paper 8.3 pricing and reimbursement policies: impacts on innovation. Priority medicines for Europe and the world "A public health approach to innovation" update on 2004 background paper 2013, World Health Organization.
96. Usher C., Tilson L., Bennett K., Barry M. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database. Clinical Therapeutics 2012, 34(3):632-639.
97. Leopold C., Mantel-Teeuwisse A.K., Vogler S., de Joncheere K., Laing R.O., Leufkens H.G.M. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy 2013, 112:209-216.
98. Dylst P., Vulto A., Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Review of Pharmacoeconomics and Outcomes Research 2013, 13(1):59-72.
99. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries-an overview. Generics and Biosimilars Initiative (GaBI) Journal 2012, 1(2):93-100.
100. World Health Organization WHO Guideline on Country Pharmaceutical Pricing Policies 2013, Geneva.
101. Dylst P., Vulto A., Simoens S. How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing?. Pharmacy Practice 2012, 10(1):3-8.
102. Vogler S., Habl C., Bogut M., Voncina L. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croatian Medical Journal 2011, 52(2):183-197.
103. Kanavos P., Schurer W., Vogler S. Pharmaceutical distribution chain in the European Union: structure and impact on pharmaceutical prices 2011, London/Vienna.
104. Stargardt T., Schreyögg J., Busse R. Pricing behaviour of pharmacies after market deregulation for OTC drugs: the case of Germany. Health Policy 2007, 84(1):30-38.
105. Statens Legemiddelverk Prisundersøkelse 2010 LUA-ordningen 2010, Oslo.
106. Almarsdóttir A.B., Traulsen J.M. Multimethod research into policy changes in the pharmacy sector-the Nordic case. Research in Social and Administrative Pharmacy 2009, 5(1):82-90.